ECSP10010556A - Piridinas y pirazinas como inhibidores de pi3k - Google Patents
Piridinas y pirazinas como inhibidores de pi3kInfo
- Publication number
- ECSP10010556A ECSP10010556A EC2010010556A ECSP10010556A ECSP10010556A EC SP10010556 A ECSP10010556 A EC SP10010556A EC 2010010556 A EC2010010556 A EC 2010010556A EC SP10010556 A ECSP10010556 A EC SP10010556A EC SP10010556 A ECSP10010556 A EC SP10010556A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirazinas
- piridines
- pi3k inhibitors
- salt
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invencion se refiere a un compuesto de la formula (I); o una sal, de una manera adecuada una sal farmaceuticamente aceptable, o un solvato del mismo, en donde los grupos R1, R2, Ar', A e Y se definen en la descripcion, a composiciones y al uso de los compuestos en el tratamiento de condiciones inflamatorias y alergicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08153045 | 2008-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010556A true ECSP10010556A (es) | 2010-11-30 |
Family
ID=39512639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010556A ECSP10010556A (es) | 2008-03-19 | 2010-10-19 | Piridinas y pirazinas como inhibidores de pi3k |
Country Status (23)
Country | Link |
---|---|
US (2) | US8268834B2 (es) |
EP (2) | EP2597085A1 (es) |
JP (1) | JP2011515362A (es) |
KR (1) | KR101284517B1 (es) |
CN (1) | CN102036961B (es) |
AR (1) | AR070923A1 (es) |
AU (1) | AU2009226958B2 (es) |
BR (1) | BRPI0909417A2 (es) |
CA (1) | CA2718526A1 (es) |
CL (1) | CL2009000650A1 (es) |
CO (1) | CO6300942A2 (es) |
CR (1) | CR11683A (es) |
EA (1) | EA018065B1 (es) |
EC (1) | ECSP10010556A (es) |
ES (1) | ES2455721T3 (es) |
IL (1) | IL208107A0 (es) |
MA (1) | MA32231B1 (es) |
MX (1) | MX2010010155A (es) |
NZ (1) | NZ587926A (es) |
PE (1) | PE20091687A1 (es) |
TW (1) | TW200948800A (es) |
WO (1) | WO2009115517A2 (es) |
ZA (1) | ZA201006506B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
WO2011053696A1 (en) * | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
MX352661B (es) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
JP2013529200A (ja) * | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN102718745A (zh) * | 2011-03-30 | 2012-10-10 | 中国科学院上海药物研究所 | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
PL2705029T4 (pl) | 2011-05-04 | 2019-04-30 | Rhizen Pharmaceuticals S.A. | Nowe związki jako modulatory kinaz białkowych |
HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
ES2899880T3 (es) | 2011-09-30 | 2022-03-15 | Vertex Pharma | Tratamiento de cáncer de páncreas y cáncer de pulmón de células no pequeñas con inhibidores de ATR |
US9458147B2 (en) | 2012-02-22 | 2016-10-04 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
IN2014KN02410A (es) | 2012-04-05 | 2015-05-01 | Vertex Pharma | |
SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
PL2870157T3 (pl) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektywne inhibitory pi3k delta |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
CA2903220C (en) | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
HUE038220T2 (hu) * | 2013-03-29 | 2018-10-29 | Takeda Pharmaceuticals Co | 6-(5-Hidroxi-lH-pirazol-1-il)nikotinamid származékok és PHD inhibitorként való alkalmazásuk |
DK3057953T3 (en) | 2013-10-17 | 2018-11-19 | Vertex Pharma | CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP3094325B1 (en) | 2014-01-14 | 2021-10-13 | Takeda Pharmaceutical Company Limited | Heteroaryls and uses thereof |
CN114181195A (zh) * | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
CN106458980A (zh) | 2014-04-24 | 2017-02-22 | 诺华股份有限公司 | 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物 |
CN106458966B (zh) * | 2014-04-24 | 2019-05-07 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
GB201715410D0 (en) * | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
MX2020009228A (es) | 2018-03-08 | 2021-01-08 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. |
WO2020010003A1 (en) * | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
KR20220100544A (ko) | 2021-01-08 | 2022-07-15 | 고려대학교 산학협력단 | PI3K/Akt 매개 후기 나트륨 전류 억제를 통한 부정맥 치료용 약학 조성물 및 치료방법 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30583A (en) * | 1860-11-06 | Milkibtg-stool | ||
GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
BE757702A (fr) | 1969-10-20 | 1971-04-19 | Sandoz Sa | Derives de la pyrido (2,3-d) pyrimidine, leur preparation et medicaments les contenant. |
US4297360A (en) * | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
EP0914318A1 (en) | 1996-05-11 | 1999-05-12 | Kings College London | Pyrazines |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
KR100439357B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ccr5 길항제로서 유용한 피페리딘 유도체 |
RU2299206C9 (ru) | 1999-05-04 | 2007-11-20 | Шеринг Корпорейшн | Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5 |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
WO2001046691A1 (en) | 1999-12-22 | 2001-06-28 | Biosignal Packard Inc. | A bioluminescence resonance energy transfer (bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use |
UA72632C2 (uk) | 2000-06-27 | 2005-03-15 | Лабораторіос С.А.Л.В.А.Т., С.А. | Карбамати, похідні від арилалкіламінів |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
CO5310534A1 (es) | 2000-08-05 | 2003-08-29 | Glaxo Group Ltd | Nuevos derivados de androstano anti-inflamatorios |
AU2002221810B2 (en) | 2000-11-07 | 2005-06-23 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
PE20020719A1 (es) | 2000-12-22 | 2002-10-11 | Almirall Prodesfarma Ag | Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3 |
DK1353919T3 (da) | 2000-12-28 | 2006-11-20 | Almirall Prodesfarma Ag | Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme |
CZ20032958A3 (en) | 2001-04-30 | 2004-03-17 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
EP1395604B1 (en) | 2001-06-12 | 2008-06-25 | Glaxo Group Limited | Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
EP2327767B1 (en) | 2001-06-21 | 2015-04-29 | BASF Enzymes LLC | Nitrilases |
EP1438309A1 (en) | 2001-10-17 | 2004-07-21 | Ucb, S.A. | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
IL162596A0 (en) | 2001-12-20 | 2005-11-20 | S A L V A T Lab Sa | 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists |
AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
WO2004052359A1 (en) | 2002-12-09 | 2004-06-24 | The Board Of Regents Of The University Of Texas System | Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
AP2114A (en) | 2003-02-26 | 2010-03-04 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
JP5283336B2 (ja) | 2004-01-12 | 2013-09-04 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | 選択的キナーゼ阻害剤 |
DE102004017934A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
AU2005276132B2 (en) | 2004-08-26 | 2011-09-29 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
MX2007001986A (es) | 2004-08-26 | 2007-05-10 | Pfizer | Compuestos de aminoheteroarilo como inhibidores de proteina quinasa. |
AU2005293556A1 (en) | 2004-10-12 | 2006-04-20 | Merck Serono Sa | PI3 Kinase gamma inhibitors for the treatment of anaemia |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20090222270A2 (en) | 2006-02-14 | 2009-09-03 | Ivc Inc. | Voice command interface device |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
CA2657200A1 (en) | 2006-07-28 | 2008-01-31 | Novartis Ag | 2,4-substituted quinazolines as lipid kinase inhibitors |
KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
GB0621607D0 (en) | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
WO2008094992A2 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
EP2173722B1 (en) * | 2007-07-26 | 2012-08-29 | Novartis AG | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AU2009227013B2 (en) | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
-
2009
- 2009-03-04 US US12/380,901 patent/US8268834B2/en active Active
- 2009-03-17 AR ARP090100956A patent/AR070923A1/es not_active Application Discontinuation
- 2009-03-17 KR KR1020107023197A patent/KR101284517B1/ko not_active IP Right Cessation
- 2009-03-17 ES ES09723200.3T patent/ES2455721T3/es active Active
- 2009-03-17 EP EP13153246.7A patent/EP2597085A1/en not_active Withdrawn
- 2009-03-17 CA CA2718526A patent/CA2718526A1/en not_active Abandoned
- 2009-03-17 MX MX2010010155A patent/MX2010010155A/es active IP Right Grant
- 2009-03-17 CN CN200980117994.2A patent/CN102036961B/zh not_active Expired - Fee Related
- 2009-03-17 EP EP09723200.3A patent/EP2257529B1/en active Active
- 2009-03-17 AU AU2009226958A patent/AU2009226958B2/en not_active Ceased
- 2009-03-17 JP JP2011500194A patent/JP2011515362A/ja active Pending
- 2009-03-17 EA EA201001455A patent/EA018065B1/ru not_active IP Right Cessation
- 2009-03-17 NZ NZ587926A patent/NZ587926A/xx not_active IP Right Cessation
- 2009-03-17 BR BRPI0909417A patent/BRPI0909417A2/pt not_active IP Right Cessation
- 2009-03-17 WO PCT/EP2009/053136 patent/WO2009115517A2/en active Application Filing
- 2009-03-18 TW TW098108819A patent/TW200948800A/zh unknown
- 2009-03-18 CL CL2009000650A patent/CL2009000650A1/es unknown
- 2009-03-18 PE PE2009000404A patent/PE20091687A1/es not_active Application Discontinuation
-
2010
- 2010-09-10 ZA ZA2010/06506A patent/ZA201006506B/en unknown
- 2010-09-13 IL IL208107A patent/IL208107A0/en unknown
- 2010-09-21 CR CR11683A patent/CR11683A/es not_active Application Discontinuation
- 2010-10-15 MA MA33251A patent/MA32231B1/fr unknown
- 2010-10-19 CO CO10129427A patent/CO6300942A2/es not_active Application Discontinuation
- 2010-10-19 EC EC2010010556A patent/ECSP10010556A/es unknown
-
2012
- 2012-04-30 US US13/460,504 patent/US8846687B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA018065B1 (ru) | 2013-05-30 |
US20090239847A1 (en) | 2009-09-24 |
US8846687B2 (en) | 2014-09-30 |
US8268834B2 (en) | 2012-09-18 |
IL208107A0 (en) | 2010-12-30 |
CR11683A (es) | 2010-10-29 |
NZ587926A (en) | 2012-08-31 |
AR070923A1 (es) | 2010-05-12 |
CA2718526A1 (en) | 2009-09-24 |
KR20100133439A (ko) | 2010-12-21 |
US20120214800A1 (en) | 2012-08-23 |
EP2597085A1 (en) | 2013-05-29 |
CN102036961A (zh) | 2011-04-27 |
WO2009115517A3 (en) | 2010-01-07 |
ES2455721T3 (es) | 2014-04-16 |
CN102036961B (zh) | 2014-02-26 |
ZA201006506B (en) | 2011-06-29 |
JP2011515362A (ja) | 2011-05-19 |
PE20091687A1 (es) | 2009-11-27 |
BRPI0909417A2 (pt) | 2015-12-08 |
KR101284517B1 (ko) | 2013-07-23 |
EP2257529A2 (en) | 2010-12-08 |
CL2009000650A1 (es) | 2010-03-26 |
CO6300942A2 (es) | 2011-07-21 |
AU2009226958B2 (en) | 2012-06-14 |
AU2009226958A1 (en) | 2009-09-24 |
TW200948800A (en) | 2009-12-01 |
WO2009115517A2 (en) | 2009-09-24 |
AU2009226958A8 (en) | 2010-10-14 |
MX2010010155A (es) | 2010-11-04 |
EP2257529B1 (en) | 2014-01-01 |
MA32231B1 (fr) | 2011-04-01 |
EA201001455A1 (ru) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
SV2011003853A (es) | Compuestos organicos | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
ECSP12011935A (es) | Triazolopiridinas | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
DK2074120T3 (da) | Tropan-forbindelser | |
CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
UY32490A (es) | Inhibidores de beta-secretasa | |
ECSP10010346A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
ECSP12012338A (es) | Triazolopiridinas sustituidas | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
UY32247A (es) | Nuevos compuestos de aminociclohexilo, composiciones farmacéuticas de los mismos y aplicaciones | |
ECSP099328A (es) | Análogos de pirazol | |
CU20100179A7 (es) | Piridinas y pirazinas como inhibidores de p13k | |
CU20100014A7 (es) | Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas | |
TN2010000426A1 (en) | Pyridines and pyrazines as inhibitors of pi3k | |
DOP2008000064A (es) | Carboxamidas sustituidas. | |
CU24174B1 (es) | Triazolopiridinas como inhibidores de quinasa mps-1 |